Anti-mycobacterial activity correlates with altered DNA methylation pattern in immune cells from BCG-vaccinated subjects by Verma, D. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/177481
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
1ScIeNtIfIc REPORtS | 7: 12305  | DOI:10.1038/s41598-017-12110-2
www.nature.com/scientificreports
Anti-mycobacterial activity 
correlates with altered DNA 
methylation pattern in immune 
cells from BCG-vaccinated subjects
Deepti Verma1, Venkata Ramanarao Parasa1, Johanna Raffetseder  1, Mihaela Martis2, 
Ratnesh B. Mehta3, Mihai Netea4 & Maria Lerm1
The reason for the largely variable protective effect against TB of the vaccine Bacille Calmette-Guerin 
(BCG) is not understood. In this study, we investigated whether epigenetic mechanisms are involved 
in the response of immune cells to the BCG vaccine. We isolated peripheral blood mononuclear cells 
(PBMCs) from BCG-vaccinated subjects and performed global DNA methylation analysis in combination 
with functional assays representative of innate immunity against Mycobacterium tuberculosis infection. 
Enhanced containment of replication was observed in monocyte-derived macrophages from a sub-
group of BCG-vaccinated individuals (identified as ‘responders’). A stable and robust differential DNA 
methylation pattern in response to BCG could be observed in PBMCs isolated from the responders 
but not from the non-responders. Gene ontology analysis revealed that promoters with altered 
DNA methylation pattern were strongly enriched among genes belonging to immune pathways in 
responders, however no enrichments could be observed in the non-responders. Our findings suggest 
that BCG-induced epigenetic reprogramming of immune cell function can enhance anti-mycobacterial 
immunity in macrophages. Understanding why BCG induces this response in responders but not in non-
responders could provide clues to improvement of TB vaccine efficacy.
Tuberculosis (TB) is one of the leading causes of death from infectious disease worldwide. The only available TB 
vaccine is Bacille Calmette Guérin (BCG), which has low efficacy against adult pulmonary TB. Since the pulmo-
nary manifestation of TB is the major source of transmission, an effective prevention strategy against pulmonary 
TB is urgently needed. New vaccine candidates are based on the addition of Mycobacterium tuberculosis (Mtb) 
antigens to the BCG regimen, however none has yet provided better protection than BCG1.
Effective vaccine development is facilitated by the use of immunological correlates, which may predict the 
outcome of vaccination. For TB vaccine research, the general strategy is to measure mycobacteria-specific T 
cell responses, however, earlier studies have failed to prove such a correlation2, suggesting that other protective 
mechanisms may be at play.
Evidence is accumulating that during lifetime, the human immune system is gradually epigenetically 
reprogrammed. Both DNA methylation changes (e.g. demethylation of transcription start sites enhances tran-
scriptional activity3) and histone modifications (e.g. histone acetylation/methylation increases or decreases 
the accessibility of DNA to transcription factors4) contribute to this phenomenon. Post-translational histone 
modifications in immune cells have been shown to result in an enhanced response to microbial stimuli5,6. 
Furthermore, altered DNA methylation has been demonstrated in a subset of natural killer (NK) cells isolated 
from cytomegalovirus-infected humans7. However, nothing is known about genome-wide DNA methylation 
changes in response to vaccination.
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Here, we investigated the effects of BCG vaccination in vivo on the DNA methylome of human immune cells. 
We demonstrate that the pattern of DNA methylation is altered in cells isolated from a subset of individuals clas-
sified as ‘responders’ based on their enhanced macrophage capacity to restrict growth of Mtb. A substantial part of 
the responders’ gene promoters that showed the strongest alteration in DNA methylation were found to be part of 
immune-related pathways. The findings suggest that altered DNA methylation could be taken into consideration 
in studies investigating why individuals respond differently to the BCG vaccine8,9.
Results
Enhanced anti-mycobacterial activity in MDMs from a subset of BCG-vaccinated individuals. 
To compare the anti-mycobacterial activity of monocyte-derived macrophages (MDMs) isolated one week 
before and 3 weeks, 4 months and 8 months after BCG vaccination, we collected peripheral blood from 8 BCG-
vaccinated individuals (Fig. 1A) at the given time points. MDMs differentiated from adherent peripheral blood 
mononuclear cells (aPBMCs) were infected with virulent Mtb. For each time point of blood sampling, the cells 
were lysed at day 0 and day 2 after infection and the relative Mtb growth (day 2/day 0) was determined by lumi-
nometry. Analysis of the ability of Mtb to replicate in the cells relative to the pre-BCG time point was com-
pared for each donor (each donor was his/her own control, applying a case series approach permitting lower 
power10). The results showed that MDMs isolated 3 weeks post-BCG from a subset of individuals (n = 4) dis-
played enhanced anti-mycobacterial capacity as compared to their MDMs isolated before vaccination (p = 0.002, 
one-sample t test) (Fig. 1B & S1). Based on this observation, and using a strategy that has been applied in previous 
studies9,11, we divided the subjects into two groups classified as responders (n = 4, enhanced anti-mycobacterial 
activity) and non-responders (n = 4). These two groups significantly differed from each other at 3 weeks post-
BCG (p = 0.03, Student’s two-tailed t test with Bonferroni correction) (Fig. 1B) and also displayed a significant 
difference over time (p = 0.001, ANOVA). The ability to control Mtb gradually waned, however, after 8 months, 
the responders were still superior to non-responders in mycobacterial control (p = 0.03, Student’s two-tailed t 
test with Bonferroni correction) (Fig. 1B). As previously reported, Mtb infection of MDMs caused cell death12, 
Figure 1. Anti-mycobacterial activity and cytokine response to mycobacterial infection of MDMs. (A) 
Diagram of the blood collection timeline. Blood was collected 1–2 weeks before (−2W) and 3 weeks, 4 months 
and 8 months post-BCG vaccination. PBMCs were isolated for DNA isolation and methylation analysis or 
used to prepare monocyte-derived macrophages for infection with luciferase-expressing Mtb. (B) MDMs’ 
anti-mycobacterial capacity (as determined by the ratio of bacterial numbers at D4/D0 in each individual 
experiment) after vs before BCG vaccination were determined using luminometry. (C) MDM cell viability at 
4 days of infection with H37Rv compared to uninfected cells from the same day as determined by calcein-AM 
fluorescence. (D) For cytokine analysis, the medium supernatant was collected at day 4 of infection and 
analyzed by cytometric bead array. Empty symbols represent responders while the solid symbols represent the 
non-responders. Statistical significance compared to before BCG was determined using Student’s one-sample 
t test, comparison between responders and non-responders was done using two-tailed Student’s t test and 
cytokines were compared using Mann-Whitney U test. *p < 0.05, **p < 0.01,***p < 0.001.
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however, the viability was similar in all conditions and time points (p = 0.09, Student’s two-tailed t test with 
Bonferroni correction Fig. 1C).
We next analyzed a set of macrophage-associated cytokines in the supernatants from the Mtb-infected MDMs 
and observed that the levels of interleukin (IL)-1β were significantly higher in the responders (IL-1β respond-
ers = 584.2 pg/ml, IL-1β non-responders = 30.39 pg/ml) at the time point before BCG vaccination (p = 0.02, 
Mann Whitney U test, corrected). All individuals displayed an increased IL-1β response after BCG vaccina-
tion, however the time point for the maximal response varied (Fig. 1D). The other analyzed pro-inflammatory 
cytokines (IL-6, IL-10, IL-12, tumor necrosis factor (TNF)-α and interferon (IFN)-γ were not significantly differ-
ent between the groups (not shown). In all unstimulated samples, the cytokines were below detection limit (not 
shown).
Genome-wide DNA methylation profiling reveals altered DNA methylation in responders. We 
next turned to investigate whether BCG would alter the DNA methylome of the PBMCs of vaccinated individuals. 
To this end, we analyzed the methylation pattern of DNA isolated from the subjects’ aPBMCs. The global DNA 
methylation of CpG sites passing the quality filtering was plotted according to the genomic locations. The overall 
DNA methylation quantified by the β value was found to be lower in the promoter region as compared to the gene 
body, 3’UTR and the intergenic regions (regions unannotated by Illumina, not shown).
At 3 weeks post-BCG, a distinct alteration of methylation (compared to the time point before BCG) was 
observed in the DNA isolated from the responders’ aPBMCs but not to the same extent in the non-responders’ 
DNA (Fig. 2A). 540 promoters displayed a more than 5-fold loss of methylation (predicted activation) in the 
responders (p < 0.01, Student’s paired t test), while only 20 promoters losing methylation were observed in the 
non-responders group at this early time point. Using the 5-fold cut-off, 477 and 183 promoters gaining methyla-
tion (predicted inactivation) were observed in responders and non-responders, respectively. Applying the same 
high stringency to the data obtained at the later time points (before BCG vs 4 months and 8 months, respectively) 
revealed a persistent differential DNA methylation in the responders. At 4 and 8 months, a substantial gain of 
DNA methylation was observed in the non-responders and a gradually increasing loss of methylation as com-
pared to the time point before BCG was also detected (Fig. 2A). Gender breakdown did not show any pattern 
(two males and two females among the responders, not shown).
The aPBMCs were analyzed by flow cytometry and shown to be composed of CD3+ T cells (~40–50%), CD14+ 
monocytes (~40%) and CD19+ B cells (~10%, not shown). In order to accurately predict the contribution of these 
individual cell types to the overall β values, we made use of the recently described Houseman algorithm13. The 
T cells contributed the most followed by the monocytes and B cells. The division of the datasets into responders 
Figure 2. Global DNA methylation changes in aPBMCs of responders and non-responders. (A) Volcano plot 
showing the differential DNA methylation at 3 weeks, 4 months and 8 months compared to the time point 
before BCG. The red dots represent the promoters where the difference in methylation (β values) as compared 
to before BCG was greater than 5-fold. Red dots on the left represent the promoters with a loss of methylation 
while those on the right represent the promoters with a gain of methylation. (B) Heat map showing the 
individual cell types’ contribution to DNA methylation. Darker color represents a higher contribution.
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and non-responders did not reveal any major difference between the contributing cell types at the different time 
points (Fig. 2B).
To interpret the functionality of the observed changes, the differentially methylated promoters were anno-
tated using the PANTHER database14. The annotation revealed a significant overrepresentation of GO terms 
related to immune system and defense response in the responders at 3 weeks post-BCG. Figure 3A visualizes 
the enriched GO terms in the responders’ data set at 3 weeks, these include terms like T cell activation, innate 
immune response, leukocyte activation and adhesion. No overrepresentations were found for the non-responder 
group at this time point. Immune process-related pathways continued to be overrepresented at 4 months in the 
responders and enrichments were found for cell communication, response to stimulus and signal transduction 
(Fig. 3A). At this time point, the non-responders displayed overrepresentations for the GO terms metabolic 
process and signal transduction (Fig. 3B). No immune-related overrepresentation could be found in either the 
responders or the non-responders at 8 months post-BCG.
To determine whether an altered DNA methylation pattern of individual promoters persisted throughout the 
8 months post BCG vaccination, the data obtained from the three time points after BCG vaccination was com-
bined in a Venn diagram (Fig. 3C). The analysis revealed that a set of 28 promoters, 6 with a loss of methylation 
and 21 with a gain, persisted in the responders throughout 8 months (Fig. 3C and Tables 1 and 2). Among the pro-
moters with persistently reduced methylation were adenylate cyclase 3 (ADCY3) and IFN-γ (IFNG). None of the 
promoters in the non-responders displayed reduced methylation at all time points (Fig. 3C). Using PANTHER, 
we also determined the pathways to which the promoters belonged that were overlapping between the 3 weeks 
and 4 months’ time points of the responders (152 with reduced and 221 with increased methylation, respectively) 
(Fig. 3D). The analysis revealed dominance of immune-related pathways.
Reduced methylation of promoters in responders’ NK cells 3 weeks post-BCG. NK cells, which 
are innate lymphocytes, have been shown to have memory characteristics15. In order to determine whether BCG 
vaccination also affected DNA methylation in NK cells, DNA was prepared from the subjects’ NK cells isolated 
before BCG and 3 weeks post-BCG vaccination and analyzed using the Illumina platform. Distinctive DNA 
methylation profiles for responders and non-responders were observed with a predominant methylation loss 
in the responders and a gain of methylation in the non-responders at 3 weeks post-BCG (Fig. 4A). The gene 
ontology analysis revealed that the gain in DNA methylation in the non-responders is overrepresented for cell 
communication and cell signaling (Fig. 4B). No overrepresentation of immune-related terms could be identified 
in the responders’ promoters, however, the promoters of NLRP3 and caspase-1, both key components of the IL-1β 
producing inflammasome, displayed reduced methylation. Further, the responders showed reduced methyla-
tion of promoters of signaling proteins like protein tyrosine phosphatases, ATP transporters, cytolytic molecules 
(granzymes) and inflammation mediators. Among the non-responders, a gain of methylation was observed in 
promoters regulating NK cell function such as NCR1 (Natural cytotoxity receptor 1), IFNG, type III IFN, gran-
zyme K as well as in the ATPases and ATP binding cassettes, interleukins and signaling molecules.
Discussion
The aim of the present study was to investigate whether BCG vaccination affects the DNA methylome of immune 
cells and whether this could be linked to an enhanced anti-mycobacterial activity in Mtb-infected macrophages. 
We took an omics approach to study global DNA methylation changes in the immune cells of BCG-vaccinated 
individuals and combined this with functional assays reflecting innate immunity directed towards Mtb. We show 
that immune cells from the individuals, whose macrophages showed increased capacity to control Mtb after BCG 
vaccination, displayed differential methylation in a large number of promoters at 3 weeks after vaccination. Thus, 
as described in previous work9, BCG induced a dichotomous response in our small, well-defined study group.
Since it has proven challenging to extrapolate the functional consequences of genome-wide DNA methylation 
alterations, we focused on altered DNA methylation in the proximity of translational start sites (TSS) regions, 
5’UTR and the first exon, as changes associated with these regions have been shown to be reflected in gene 
expression16,17. The gene ontology analysis revealed that immunity-related pathways were enriched for differen-
tially methylated promoter-proximate regions at 3 weeks after BCG in the responders’ immune cells. This effect 
persisted through 4 months in accordance with a recent study showing BCG-induced histone modifications in 
monocytes 3 months post-vaccination18. In addition, the 152 promoters with reduced and 221 with enhanced 
DNA methylation, respectively, that were stable from 3 weeks through 4 months post-vaccination were strongly 
enriched for immune-related pathways. We detected persistently reduced methylation of the promoter of the 
adenylate cyclase (AC) gene ADCY3 at all time points in the responders. Of note, recent studies have shown that 
ADCY3 is linked to the increased cytokine production that accompanies trained immunity19. In addition, the 
promoter of IFNG remained in a reduced methylated state in the responders throughout the duration of the study. 
IFN-γ is well-established as one of the most crucial factors that allow the immune system to control mycobacte-
rial infection6,20. It could be argued that these persisting effects of BCG in the responders are due to the presence 
of BCG organisms in the body, thus being a more direct effect of BCG on the immune cells rather than an epige-
netic memory of the exposure. Indeed, the persistence of BCG in the body has been shown to last for about one 
month post-BCG21, hence, the present study cannot rule out that this contributes to the observed effects.
We demonstrate that individuals, whose MDMs had an inherent ability to respond to Mtb exposure by an 
increased IL-1β production responded to the vaccine by enhancing MDM efficacy in controlling the replication 
of Mtb. This is reminiscent of the increased antifungal killing in models of trained immunity induced in mac-
rophages by β-glucan22. The present study does not unravel whether IL-1β acts upstream or downstream of the 
induction of epigenetic reprogramming. However, the involvement of this cytokine for the establishment of anti-
microbial defense mechanisms via induction of trained immunity is supported by studies showing that injection 
of IL-1β before infection can protect against infection with Pseudomonas aeruginosa or Candida albicans23,24.
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While the adaptive immune responses to BCG are very well-studied, the understanding of the effects of this 
vaccine on other aspects of immunity is only emerging. Early studies conducted in the years after the introduc-
tion of BCG in vaccination programs showed that BCG protected against TB-unrelated child mortality25 and 
more recent studies have confirmed these findings26–29. These effects have been suggested to be induced through 
Figure 3. Gene Ontology analysis of differentially methylated promoters in responders and non-responders. 
(A–B) Gene ontology analysis using PANTHER with the DNA methylation data at 3 weeks, 4 months and 
8 months describing the overrepresented biological pathways on the Y- axis and log 10 adjusted p values 
(<0.01) on the X- axis. Immune function-related pathways are represented as red bars. No enrichments were 
found for the non-responders at 3 weeks’ time point. (C) Venn diagram showing the overlap of differentially 
methylated promoters (represented as absolute numbers) at 3 weeks (pink), 4 months (blue) and 8 months 
(green). Numbers within brackets show the corresponding percentages of total hypo or hyper-methylated 
promoters. (D) gene ontology analysis of the promoters overlapping between the 3 weeks’ and 4 months’ time 
point in the responders. No corresponding enrichments were found for the non-responders. Promoters with a 
loss of methylation are shown in the white bubbles and those with a gain of methylation are shown in the black 
bubbles. Abbreviations: pr = process, reg = regulation.
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epigenetic reprogramming30,31. Trained immunity is generated independently of functional T- and B cells and 
involves histone modifications induced via a Nod2-mediated pathway5. The present study adds DNA methylation 
alterations to this concept.
NK cells were recently found to respond to BCG vaccination by an increase in IL-1β production15. Here, 
responders’ NK cells displayed decreased methylation of both NLRP3 and caspase-1 promoters, which is indica-
tive of facilitation of IL-1β production. NK cells are suggested to have a role in the early clearance of Mtb infection 
due to their early appearance and evidence in Mtb killing and macrophage apoptosis32.
The small sample size of the present study limits extrapolation of the findings, however, for any studies on 
changes in the DNA methylome, intervention studies like this allows the comparison of data from each individual 
before vs. after intervention, which allows interpretation of data from a smaller sample size. Since DNA methy-
lome patterns varies greatly by ethnicity, age, environmental factors and possibly seasonal changes, it is attractive 
to focus on a well-defined study group assessed at several time points before and after an intervention like vac-
cination. From the present study, no conclusions can be drawn on a possible correlation between BCG-induced 
epigenetic changes and vaccine efficacy. Hence, future studies in TB-endemic settings are warranted to assess 
whether altered epigenetic changes in response to BCG vaccination could be predictive of protection against TB.
Materials and Methods
Ethics statement. The study protocol was approved by the local ethics committee in Linköping (Etik 
prövningsnämnden #2013/203-31). All individuals signed an informed consent to participate in the study. All 
experimentation was performed in accordance with the Declaration of Helsinki. All samples were deidentified 
making any tracing of subjects impossible.
Study subjects. 70 ml blood were collected in heparinized tubes 1–2 weeks prior to BCG vaccination 
and 3 weeks, 4 months and 8 months after the vaccination from 8 healthy individuals. The subjects were all 
non-smoking, PPD-negative, Swedish-born Caucasians (20–35 years, mean age 24 years, 5 males) with normal 
BMI and no history of BCG vaccination.
GENE SYMBOLS DESCRIPTION
IFNG Interferon gamma
RASAL1 RasGAP-activating-like protein 1
GIMAP7 GTPase IMAP family member 7
ADCY3 Adenylate cyclase type 3
ATXN1 Alterernative reading frame 1
DIABLO Direct IAP-Binding Protein With Low PI
Table 1. Promoters displaying persistent differential methylation at all time points: Responders. Loss of DNA 
methylation.
GENE SYMBOLS DESCRIPTION
TLR6 Toll-like receptor 6
SRD5A2 3-oxo-5-alpha-steroid 4-dehydrogenase 2
SOX5 Transcription factor SOX-5
GNG7 G nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7
SBNO2 Protein strawberry notch homolog 2
SULT1C Sulfotransferase 1 C
NFKBIE NF-kappa-B inhibitor epsilon
TRIM2 Tripartite motif-containing protein 2
GPR84 G-protein coupled receptor 84
SPATS2 Spermatogenesis-associated serine-rich protein 2
CD59 Complement regulatory protein
ATXN1 Alternative reading frame 1
NCOR2 Nuclear receptor co-repressor 2
ADARB1 Adenosine deaminase
LOC404266 Undefined function
SRGAP3 SLIT-ROBO RHO GTPase-activating protein 3
PIWIL2 PIWI-like 2
SPG20 Spastic paraplegia 20
TSPAN4 Tetraspanin4
CSGALNACT1 Chondroitin sulphate N-acetylgalactosaminyltransferase 1
Table 2. Promoters displaying persistent differential methylation at all time points: Responders: Gain of DNA 
methylation.
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Bacteria. Mtb H37Rv (ATCC) carrying the luciferase-encoding pSMT1 plasmid was cultured as previously 
described33.
Isolation of mononuclear cells. PBMC were separated by density centrifugation on Lymphoprep as previ-
ously described34 and either frozen (at −150 °C, 3 months and 8 months’ time point) or seeded (the ‘before BCG’ 
and the ‘3 weeks post BCG’ time points) in cell culture flasks, allowing enrichment of adhesive cells. Following 
adherence, the non-adherent lymphocytes were washed off. Cells were either trypsinized to isolate genomic DNA 
or allowed to differentiate into macrophages as previously described34. Phenotyping of the adherent cells was 
performed by flow cytometry (not shown).
Figure 4. Global DNA methylation changes in NK cells from responders and non- responders (A) Volcano plot 
showing the DNA methylation pattern in NK cells at 3 weeks compared to before BCG. The red dots represent 
the promoters where the difference in methylation β values as compared to before BCG was greater than 5-fold. 
Red dots on left represent the promoters with a loss of methylation while those on right represent the promoters 
with a gain of methylation. (B) Gene ontology analysis of differentially methylated promoters in NK cells at 
three weeks. The graphs depict the overrepresented biological pathways on the Y- axis and log 10 adjusted p 
values (<0.01) on the X- axis.
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Purification of NK cells. NK cells were purified from the non-adherent fraction of the PBMCs by magnetic 
bead separation using the human NK cell isolation kit (Miltenyi Biotec GmbH, Gladbach, Germany). Purity as 
determined by flow cytometry was >95%.
Flow cytometry. Phenotyping of the adherent cells was performed by flow cytometry. Cells were labelled 
using mouse anti-human monoclonal antibodies (CD3-FITC, CD56-PE, CD14-APC, CD16b-PE and CD19-PE, 
BD Biosciences, San Jose, CA, USA) for 30 mins at 4 °C before washing and resuspension in PBS and detected 
using a Gallios flow cytometer (Beckman Coulter, USA). Analysis of the flow cytometric data was performed with 
Kaluza Analysis software version 1.3 (Beckman Coulter, USA).
Mycobacterial replication and macrophage viability. Infection using luciferase-expressing H37Rv at 
a multiplicity of infection of 5 was performed as previously described35 and bacterial load and cell viability was 
determined at day 0 and day 4. Cell supernatants were collected, centrifuged and stored at −70 °C for cytokine 
determination.
Cytokine measurements. The cytokines were determined using the human flex sets for Cytometric Bead 
Array (IFN-γ using Human IFN-γ Enhanced Sensitivity Flex Set, Becton Dickinson), followed by 30 min 4% par-
aformaldehyde fixation. Data were acquired on a Gallios Flow Cytometer and analyzed using its Kaluza software 
(Beckman Coulter).
DNA extraction and Infinium Methylation Assay. DNA was isolated from NK cells and the aPBMCs 
using QiAmp DNA isolation kit following the instructions. DNA concentration was measured by Qubit fluo-
rometer. DNA samples were bisulphite converted, amplified, fragmented and hybridized to an Illumina Infinium 
Human Methylation 450 K Bead Chip and scanned.
Bioinformatic analysis. The raw data was imported into R version 3.2.2 and analyzed using the Bioconductor Minfi 
package. Background correction and within-array subset quantile normalization were implemented. Probes over-
lapping with SNPs, or having a detection p value > 0.01 as well as the probes present on the X and Y chromosomes 
were excluded. The β values (0–1) were derived from the processed data defined as the ratio of methylated probe 
intensity to the sum of methylated and unmethylated probe intensity. The methylation for genomic regions was 
calculated as average β value for all probes located within the regions annotated by Illumina: Transcription start 
site (TSS)200, TSS1500, 5’untranslated region (UTR), 1st exon, gene body, 3’UTR and intergenic (unannotated) 
region. Promoters were defined as covering the TSS, 5’UTR and first exon. Differentially methylated (DM) loci 
were determined using a paired Student’s t-test and were selected if the fold change in β value exceeded 5% with 
corresponding p values less than 0.01. The differential DNA methylation analysis has been performed with sup-
port from NBIS (National Bioinformatics Infrastructure Sweden).
Gene function annotation and pathways analyses. The functions of differentially methylated pro-
moters were annotated using the PANTHER database (http://www.pantherdb.org/). The official gene symbols 
were used as input to calculate the statistical over-representation of biological process GO terms using a binomial 
test. Only pathways with a Bonferroni corrected p value < 0.01 were considered significant and top 20 pathways 
of them are presented.
Estimating contribution of different cell types. To estimate the relative proportion of different cells 
types in the aPBMC samples the Houseman correction was implemented in Minfi (FlowSorted.Blood.450 k), 
which is especially developed for Illumina 450 K arrays13,36. The algorithm combines the user’s input intensity data 
with the flow-sorted data, normalizes the data and then estimates the cell composition37.
Data availability statement. The Illumina datasets will be available at the Gene Expression Omnibus 
database at NCBI (https://www.ncbi.nlm.nih.gov/geo/).
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